Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 16 November →